Metraipolis › archive › dc_4871e9b33fca

Remarkable response to CDK4/6 inhibitor-based endocrine therapy in HR+/HER2- metastatic male breast cancer with visceral crisis: a case report — Europe PMC PMID:41551151

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41551151
DOI
10.3389/fonc.2025.1753700
License (as archived)
solo-consultazione
Archived
2026-11-07T03:00:05.742Z
SHA-256 of the archived text
9641924f1e0a93355866c08cb0f122c7d5d473c57749d462e127cbddde3767f4
Stable URL of this page
https://metraipolis.com/documento/dc_4871e9b33fca

How to cite

Remarkable response to CDK4/6 inhibitor-based endocrine therapy in HR+/HER2- metastatic male breast cancer with visceral crisis: a case report — Europe PMC PMID:41551151 — Europe PMC (en), https://europepmc.org/article/MED/41551151 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4871e9b33fca (Metraipolis archive dc_4871e9b33fca, sha256 9641924f1e0a93355866c08cb0f122c7d5d473c57749d462e127cbddde3767f4)
BibTeX
@misc{dc4871e9b33fca,
  title = {Remarkable response to CDK4/6 inhibitor-based endocrine therapy in HR+/HER2- metastatic male breast cancer with visceral crisis: a case report — Europe PMC PMID:41551151},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41551151},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4871e9b33fca; sha256 9641924f1e0a93355866c08cb0f122c7d5d473c57749d462e127cbddde3767f4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41551151. Agents can read the archived copy with the MCP tool read_document.